

Form CT 11

PHARMACY, MEDICINES & POISONS BOARD

SERIOUS ADVERSE EVENT FORM

PMPB Office Use Only

· 2 •						
PMPB Office Phone: 265-1755166/16	65					
PMPB Office Fax: 265-1755204						
Record Number	Protocol Ref Number					
Received Date Stamp	Report Received by:Mail	Fax				
T	ype of Report:InitialUpdate					
Site Report Date:\\\\	Site Awareness Date:	\\\\\\\\				
Event Previously Reported: Yes	No					
Clinical Site:	Telephone Number: ()					
Completed by: (Print name/	Signature: (title)					
Trials Program (Circle)	Protocol Number Volunteer	ID Number				
Age: Years/Months/Days (Circle	e) Sex: Male Female					
COMPLETE ONE SAE FOR	M FOR <u>EACH</u> REPORTABLE EVENT					
1. PRIMARY REASON SAE IS BEI	ING REPORTED (Check One Category)					
DeathCancerCongenital anomaly/Birth defectPermanent disability/Incapacity	Overdose or error in administration HIV InfectionImmune dysfunctionGrade 3 or 4 event	Grade 1 or 2 eventRecurrent eventOtherOther				

TOX	CITY GRADE (1-5)				
3. SAI	ONSET DATE:\\\\\ STUDY WEEK:YesNo				
4. VISIT NUMBER: IDENTIFIED POST-STUDY:YesNo					
5. IN\	ESTIGATIONAL PRODUCT				
A. V	ACCINE PRODUCTS (List ALL immunization date - DD MM YY				
1	\\\\\\\\\\\\\				
2	_ _ _ 4_ _ 6_ _ 8_ _				
B. NO	I-VACCINE PRODUCTS				
Start D	te:\N				
onset:	oute, schedule at SAE				
onset: 6. MA					
6. MA C Redu 	NAGEMENT OF STUDY TREATMENT (Check One Response) IntinuedTemporarily heldOff Investigational Product at SAE onset or				
onset: 6. MACRedu 7.	AGEMENT OF STUDY TREATMENT (Check One Response) IntinuedTemporarily heldOff Investigational Product at SAE onset or ced dose or schedulePermanent discontinued treatment course completed EVENT SUMMARY Include clinical of event, associated signs and symptoms, alternative etiologies being considered,				
onset: 6. MACRedu 7.	AGEMENT OF STUDY TREATMENT (Check One Response) IntinuedTemporarily heldOff Investigational Product at SAE onset or ced dose or schedulePermanent discontinued treatment course completed EVENT SUMMARY Include clinical of event, associated signs and symptoms, alternative etiologies being considered,				
onset: 6. MACRedu 7.	AGEMENT OF STUDY TREATMENT (Check One Response) IntinuedTemporarily heldOff Investigational Product at SAE onset or ced dose or schedulePermanent discontinued treatment course completed EVENT SUMMARY Include clinical of event, associated signs and symptoms, alternative etiologies being considered,				
6. MA C Redu 	AGEMENT OF STUDY TREATMENT (Check One Response) IntinuedTemporarily heldOff Investigational Product at SAE onset or ced dose or schedulePermanent discontinued treatment course completed EVENT SUMMARY Include clinical of event, associated signs and symptoms, alternative etiologies being considered,				

							
B. CONCOMITANT MEDI	CATIONS						
B. CONCOMITANT MEDI List ALL non-study Conce		being taken one	month prior to SAF or	nset			
below, or attach a copy							
1	2		5				
2	4		6				
9. RELEVANT LABORATO	DRY TESTS						
Complete the table below, or ser	nd copies of data forr	ns or other lab s	lips with equivalent				
nformation.							
Lab Test Abnormal Result	Site Normal Range	Collection Date	(DD/ MM / YY)	Lab Value			
Previous or subsequent to this e			(DD/ MM / YY)	Lab value			
·			,				
Dalatianahin at CAE ta luwatinat	kiamal Duadousk (Olaso	al. On a Dannana	`				
Relationship of SAE to Investigat	ional Product: (Chec	ж <u>One</u> Response)				
Pro	bablyPos	sibly	_Not Related				
Physician Signature:			Г	Date: \ \			
Physician Signature: Signature indi	cates review and app	proval of data pro	ovided	Julio \ \ \			
Physician Name Printed:							
Trysician Name Filited							
INSTRUCTIONS FOR COMPLE	TING THE SEDIOUS	ADVEDSE EVENT	(SAF)				
	EADER INFORMATION		(JAL)				
Shaded Box:	Do Not Write in	this Box. This is fo	or PMPB Office use only.				
Site Report Date:		Enter the date the SAE Form was completed by the site. Enter the date the site first became aware OR was					
	first notified of the		e aware OR was				
Event Previously Reported:			it indicates				
rom reviews, reperteur		Check the appropriate response that indicates whether or not this event has Site Awareness					
	Date:been previ	ously reported on a	an SAE form.				
Clinical Site:	nical Site: Print the name of the clinical trial title reference						
elephone Number:		Provide the most appropriate telephone number should the PMPB Office need to contact the site to obtain additional information					
completed by:			on filling out the SAE Fo	rm			
rials Program:	Circle the trials p	rogram that your c	linical site is affiliated w	ith			
rotocol Number:	Enter the oral pro	otocol number that	this volunteer is curren	tly enrolled in			
/olunteer ID Number:			d in the trial to identify t circle the appropriate un				
lge: Sex:		riate sex of the vol		iit.3			
TERA 1							
TEM 1 Shock one (1) primary reason this S	AF is boing						
Check one (1) primary reason this S	AL IS DEILIG						

reported

<u>ITEM 2</u>
Reportable SAE: Enter a key word, laboratory parameter, diagnosis or cause of death on the line provided.

Toxicity Grade: Enter a toxicity grade (1-5) to indicate the severity of the event being reported.

ITEM₃

SAE Onset Date: Enter the date when the SAE first occurred at this toxicity grade level.

(For SAEs which are lab abnormalities, use the specimen collection date).

Study Week: Enter the week of study (counting from enrollment) during which the event occurred.

ITEM₄

Visit Number: Enter the visit number when the SAE was first assessed. If Unscheduled Visit: Record the two digit Visit Code for the most recent

scheduled visit. **Note:** Use this code even when that scheduled visit was **not completed.** Use the guide below to complete the third box (after the decimal point). **Num Visit Type**

1. First Unscheduled Visit after the most recent scheduled visit.

2. Second Unscheduled Visit after the most recent scheduled visit.

Identified Post-Study: If this serious Adverse Event has been identified by the site in the Post-Study period, then Study Week and Visit Number do not need to be completed.

ITEM 5

A.

Vaccine Products: Sequentially list the dates of all immunizations received by the volunteer. For protocols where a "dose" of vaccine product consists of sequential immunizations, include the schedule of administration in item #7 or in an attached summary.

B. Non-Vaccine Products:

Start Date: Enter the Initial Date that the volunteer began taking the Investigational Product. **Date Last Administered**: Enter the <u>Last Date</u> that the volunteer received the Investigational Product. If the volunteer is being <u>continued</u> on the Investigational Product, this date field should be left blank.

Dose, route schedule at SAE onset: Enter the dose, route and schedule that was administered at the time of the SAE onset.

<u>ITEM</u> 6

Check the appropriate response that represents the management of the study treatment as a result of the SAE.

ITEM 7

Summarize the event in the space provided, or attach a narrative summary. Include all relevant information and details surrounding the event.

ITEM₈

List the concomitant medications taken one month prior to/at SAE onset which may have contributed to the event or attach a copy of the medication profile.

<u> ITEM</u> 9

If the SAE being reported is a lab Abnormality, complete the Table provided OR attach copies of Laboratory Reports. Remove personal identifiers from copies of medical record documents, and include only the volunteer ID number. If the SAE being reported is a Clinical Event, enter the laboratory information which is relevant to the diagnosis or clinical event.

ITEM 10

Signature of an Investigator or Subinvestigator Physician listed on the clinical trial protocol approved by PMPB, who has reviewed and verified the data on the SAE Form for accuracy and completeness and has assessed the relationship of the SAE to study treatment.